Business
MediPharm Labs Corp. Announces Voting Results From Special Meeting of Shareholders
MediPharm Labs Corp. Announces Voting Results From Special Meeting of Shareholders Cana...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n \n \n \n MediPharm Labs Corp. Announces Voting Results From Special Meeting of Shareholders\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n BARRIE, ON\n \n \n ,\n \n \n March 21, 2023\n \n \n /CNW/ -\n \n MediPharm Labs Corp\n \n . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (\"MediPharm\", or \"MediPharm Labs\") is pleased to announce that the shareholders of MediPharm (the \"Shareholders\") have approved the plan of arrangement under section 192 of the\n \n Canada Business Corporations Act\n \n (the \"Arrangement\"), previously announced on\n \n December 22, 2022\n \n , pursuant to which MediPharm will acquire all of the issued and outstanding common shares (\"VIVO Shares\") of VIVO Cannabis Inc. (\"VIVO\") in an all-equity business combination transaction. 47,742,357 votes, or approximately 94.063% of the votes cast at the special meeting of Shareholders held on\n \n March 21, 2023\n \n , were cast in favour of the resolution approving the issuance of the common shares of MediPharm (the \"MediPharm Shares\") as consideration under the Arrangement. Details of the voting results will be filed under MediPharm's profile on SEDAR at\n \n www.sedar.com\n \n .\n \n \n \n \n \n \n \n \n \n In accordance with the terms of the arrangement agreement dated\n \n December 21, 2022\n \n between VIVO and MediPharm, if the Arrangement becomes effective, the shareholders of VIVO (the \"VIVO Shareholders\") (other than dissenting VIVO Shareholders) will receive between 0.2110 of a MediPharm Share and 0.4267 of a MediPharm Share for each VIVO Share held. Upon the completion of the Arrangement, existing Shareholders are expected to own between 65% and 79% of the combined company resulting from the Arrangement (the \"Combined Company\") and shareholders of VIVO are expected to own between 35% and 21% of the Combined Company.\n \n \n Completion of the Arrangement is subject to court approvals, and the satisfaction or waiver of other customary closing conditions. The Arrangement has been approved by VIVO Shareholders at the special meeting of...